HUTCHMED (NASDAQ:HCM) Shares Gap Down – Should You Sell?

HUTCHMED (China) Limited (NASDAQ:HCM) gapped down prior to trading on Monday . The stock had previously closed at $15.58, but opened at $15.18. HUTCHMED shares last traded at $14.85, with a volume of 12,786 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Stock Down 0.3 %

The firm has a 50 day moving average price of $18.30 and a 200-day moving average price of $18.22. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.

Hedge Funds Weigh In On HUTCHMED

Several large investors have recently made changes to their positions in the business. Rhumbline Advisers increased its holdings in HUTCHMED by 8.1% in the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after buying an additional 564 shares during the period. Vanguard Personalized Indexing Management LLC raised its position in HUTCHMED by 9.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock worth $226,000 after purchasing an additional 1,168 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of HUTCHMED during the third quarter valued at $35,000. China Universal Asset Management Co. Ltd. lifted its position in HUTCHMED by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after purchasing an additional 2,321 shares during the period. Finally, Blue Trust Inc. lifted its holdings in HUTCHMED by 638.2% in the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after buying an additional 3,057 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.